Two Canadian inventions give hope to Alzheimer’s patients

Views: 140

Wearable low-level Light Therapy devices show beneficial effects

Highly connected hubs of the default mode network have been selected for photobiomodulation

Last year, a randomized placebo-controlled pilot study using wearable devices, the patented Vielight 810 Infrared and patent-pending Vielight Neuro, was conducted involving 19 patients affected by Alzheimer’s disease or dementia.

The findings showed surprisingly promising outcomes. The devices were developed by Vielight Inc. of Toronto, Canada.

This could be the first randomized controlled human study that has presented the arrest or reversal in the decline of Alzheimer’s Disease. The patients used the “Neuro” for 20 minutes once or twice a week and the “Vielight 810” every day for 25 minutes. The results of this pilot study are significant and strongly suggest that the treatment for people with moderate-severe cognitive impairment can result in significant clinical improvements. People with this level of cognitive impairment are excluded as candidates for pharmaceutical drugs under development or in clinical trials.

ALSO READ:   Drink coffee for better and efficient team work

The details of this study (co-authors include Dr. Margaret Naeser, a research professor of neurology at the Boston University School of Medicine, Dr. Michael Hamblin, and associate professor at Harvard Medical School) are now being written into a peer-reviewed paper for publication.

The Vielight Neuro is designed to direct pulsed near infrared light (NIR) to the targeted brain hubs

TECHNOLOGY: The technology involved the science of low level light therapy (LLLT) or photobiomodulation therapy (PBMT). PBMT is a process in which exposure to low-level light or light emitting diodes stimulate cellular function leading to beneficial clinical effects. Prior to this study, research has already presented its potential with dementia and Alzheimer’s disease (AD) in its successful effect on animals with AD. Vielight has translated the research into non-invasive wearable devices which were used in this study.

ALSO READ:   Anupam Kher hopes to create awareness on relevant social issues

KEY EVENT: An abstract was submitted to the Alzheimer’s Association and has been accepted for poster presentation at the Alzheimer’s Association International Conference.

Location and date
Pre-conferences: July 22-23
Exhibit dates: July 24-27
Annual conference: July 24-28
Metro Toronto Convention Centre
222 Bremner Blvd.
Toronto, ON M5V 3L9

LARGE CLINICAL TRIAL IN DESIGN: The MaRS Excellence in Clinical Innovation Technology Evaluation (EXCITE) program has selected Vielight Inc., as its newest participant. The EXCITE program will support Vielight on its path to achieve adoption by health systems in Canada, The United States and the United Kingdom to treat memory and cognitive decline in patients suffering from dementia and Alzheimer’s disease.

“As an EXCITE board member, the chair of the Council of Academic Hospitals of Ontario, the CEO of the Centre for Addiction and Mental Health and a neurologist, I deeply understand the tragedy of neurodegenerative conditions that cause dementia and their impact on individuals and their loved ones. I’m very enthusiastic about the opportunity to evaluate Vielight’s photobiomodulation technology with EXCITE’s support. If this clinical trial validates early findings it will create hope for a major breakthrough in dementia care,” said Dr. Catherine Zahn.

“Our goal with the feasibility study (aside from examining the effects) was to look at the practical challenges faced by patients and caregivers coming to a clinic for treatment that would help with a formal clinical trial design. The outcomes exceeded our expectations,” said principal investigator Anita Saltmarche.- CNW

ALSO READ:   Canadian Senate approves marijuana legalisation bill
Comments: 1

Your email address will not be published. Required fields are marked with *